The rationale for the deal appears to be the increasing competition in the blood plasma ... chart should, however, help the two groups avoid the anti-trust issues that derailed Talecris’s ...

The Spanish firm also is assuming $600 million in Talecris debt. Grifols will pay $19 in cash plus 0.641 ... Shares in Talecris, which operates a huge plasma manufacturing facility in Clayton ...

Both Talecris and CSL sell products made from human plasma, a substance found in the blood. The drugs are used to treat autoimmune disorders and other conditions. It’s a profitable, fast-growing ...

MADRID (Reuters) - Spain's Grifols has agreed to buy U.S.-based Talecris Biotherapeutics , which makes plasma-based protein medicines, for $3.4 billion in a bold move to expand its business in ...

The company said it would use about $515 million in proceeds to pay loans ... Founded in 2005, Talecris makes a range of plasma-derived protein therapies, including intravenous treatments for ...

Talecris Therapeutics expects to move ahead with its $270 million expansion plan at the huge Clayton blood plasma plant even though the RTP-based firm is being sold. Talecris Therapeutics (Nasdaq ...